Jeffery M Venner1,2, Konrad S Famulski1,3, Jeff Reeve1,3, Jessica Chang1, Philip F Halloran1,2. 1. Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada. 2. Department of Medicine, Division of Nephrology and Transplant Immunology, Edmonton, Alberta, Canada. 3. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Abstract
BACKGROUND: Kidney transplant biopsies offer an opportunity to understand the pathogenesis of organ fibrosis. We studied the relationships between the time of biopsy after transplant (TxBx), histologic fibrosis, diseases, and transcript expression. METHODS: Expression microarrays from 681 kidney transplant indication biopsies taken either early (n = 282, <1 year) or late (n = 399, >1 year) after transplant were used to analyze the molecular landscape of fibrosis in relationship to histologic fibrosis and diseases. RESULTS: Fibrosis was absent at transplantation but was present in some early biopsies by 4 months after transplant, apparently as a self-limited response to donation implantation injury not associated with progression to failure. The molecular phenotype of early biopsies represented the time sequence of the response to wounding: immediate expression of acute kidney injury transcripts, followed by fibrillar collagen transcripts after several weeks, then by the appearance of immunoglobulin and mast cell transcripts after several months as fibrosis appeared. Fibrosis in late biopsies correlated with injury, fibrillar collagen, immunoglobulin, and mast cell transcripts, but these were independent of time. Pathway analysis revealed epithelial response-to-wounding pathways such as Wnt/β-catenin. CONCLUSION: Fibrosis in late biopsies had different associations because many kidneys had potentially progressive diseases and subsequently failed. Molecular correlations with fibrosis in late biopsies were independent of time, probably because ongoing injury obscured the response-to-wounding time sequence. The results indicate that fibrosis in kidney transplants is driven by nephron injury and that progression to failure reflects continuing injury, not autonomous fibrogenesis. TRIAL REGISTRATION: INTERCOM study (www.clinicalTrials.gov; NCT01299168). FUNDING: Canada Foundation for Innovation and Genome Canada.
BACKGROUND: Kidney transplant biopsies offer an opportunity to understand the pathogenesis of organ fibrosis. We studied the relationships between the time of biopsy after transplant (TxBx), histologic fibrosis, diseases, and transcript expression. METHODS: Expression microarrays from 681 kidney transplant indication biopsies taken either early (n = 282, <1 year) or late (n = 399, >1 year) after transplant were used to analyze the molecular landscape of fibrosis in relationship to histologic fibrosis and diseases. RESULTS:Fibrosis was absent at transplantation but was present in some early biopsies by 4 months after transplant, apparently as a self-limited response to donation implantation injury not associated with progression to failure. The molecular phenotype of early biopsies represented the time sequence of the response to wounding: immediate expression of acute kidney injury transcripts, followed by fibrillar collagen transcripts after several weeks, then by the appearance of immunoglobulin and mast cell transcripts after several months as fibrosis appeared. Fibrosis in late biopsies correlated with injury, fibrillar collagen, immunoglobulin, and mast cell transcripts, but these were independent of time. Pathway analysis revealed epithelial response-to-wounding pathways such as Wnt/β-catenin. CONCLUSION:Fibrosis in late biopsies had different associations because many kidneys had potentially progressive diseases and subsequently failed. Molecular correlations with fibrosis in late biopsies were independent of time, probably because ongoing injury obscured the response-to-wounding time sequence. The results indicate that fibrosis in kidney transplants is driven by nephron injury and that progression to failure reflects continuing injury, not autonomous fibrogenesis. TRIAL REGISTRATION: INTERCOM study (www.clinicalTrials.gov; NCT01299168). FUNDING: Canada Foundation for Innovation and Genome Canada.
Authors: Joan C Smith; Braden E Boone; Susan R Opalenik; Scott M Williams; Shirley B Russell Journal: J Invest Dermatol Date: 2007-11-08 Impact factor: 8.551
Authors: M Mengel; J Reeve; S Bunnag; G Einecke; B Sis; T Mueller; B Kaplan; P F Halloran Journal: Am J Transplant Date: 2008-10-31 Impact factor: 8.086
Authors: Philip F Halloran; Jessica Chang; Konrad Famulski; Luis G Hidalgo; Israel D R Salazar; Maribel Merino Lopez; Arthur Matas; Michael Picton; Declan de Freitas; Jonathan Bromberg; Daniel Serón; Joana Sellarés; Gunilla Einecke; Jeff Reeve Journal: J Am Soc Nephrol Date: 2014-11-06 Impact factor: 10.121
Authors: Matthew J Vitalone; Philip J O'Connell; Moses Wavamunno; Caroline L-S Fung; Jeremy R Chapman; Brian J Nankivell Journal: Transplantation Date: 2010-03-15 Impact factor: 4.939
Authors: Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: D G Maluf; C I Dumur; J L Suh; J K Lee; E P Cathro; A L King; L Gallon; K L Brayman; V R Mas Journal: Am J Transplant Date: 2014-04-02 Impact factor: 8.086
Authors: M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel Journal: Am J Transplant Date: 2014-02 Impact factor: 8.086
Authors: Jeremie M Lever; Travis D Hull; Ravindra Boddu; Mark E Pepin; Laurence M Black; Oreoluwa O Adedoyin; Zhengqin Yang; Amie M Traylor; Yanlin Jiang; Zhang Li; Jacelyn E Peabody; Hannah E Eckenrode; David K Crossman; Michael R Crowley; Subhashini Bolisetty; Kurt A Zimmerman; Adam R Wende; Michal Mrug; Bradley K Yoder; Anupam Agarwal; James F George Journal: JCI Insight Date: 2019-01-24
Authors: Philip F Halloran; Jeff Reeve; Arezu Z Aliabadi; Martin Cadeiras; Marisa G Crespo-Leiro; Mario Deng; Eugene C Depasquale; Johannes Goekler; Xavier Jouven; Daniel H Kim; Jon Kobashigawa; Alexandre Loupy; Peter Macdonald; Luciano Potena; Andreas Zuckermann; Michael D Parkes Journal: JCI Insight Date: 2018-10-18
Authors: Philip F Halloran; Jeff Reeve; Katelynn S Madill-Thomsen; Zachary Demko; Adam Prewett; Paul Billings Journal: J Am Soc Nephrol Date: 2022-01-20 Impact factor: 10.121
Authors: Erika T Rhone; Elissa Bardhi; Sai Vineela Bontha; Patrick D Walker; Jorge A Almenara; Catherine I Dumur; Helen Cathro; Daniel Maluf; Valeria Mas Journal: Int J Mol Sci Date: 2021-05-21 Impact factor: 5.923